RecruitingNot ApplicableNCT05223608
Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy
Sponsor
Centre Oscar Lambret
Enrollment
651 participants
Start Date
Mar 3, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
ImmuCCo-1905 is a monocentric interventional study on patients treated by immunotherapy, which consist in establishment of a prospective clinic-biologic database over 5 years, associated with a biobank. This database will allow carrying out works aiming at assessing immunotherapy in real life situation.
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- Age ≥ 18 years
- Beginning a first immunotherapy by immune checkpoint inhibitor - anti-PD1 (Programmed cell Death protein-1), anti-PDL1 (Programmed cell Death protein-1 ligand), anti-CTLA4 (Cytotoxic T-Lymphocyte associated protein 4), as monotherapy or in combination, in the Centre Oscar Lambret (COL)
- In neo-adjuvant, adjuvant, recurrence or metastatic situation
- Suffering from solid tumor histologically documented
- Signed written informed consent
- Patient covered by the French " "Social Security" regime If the patient is already enrolled in clinical trial involving immunotherapy, the agreement of the sponsor of this new trial will be sought before his/her inclusion.
Exclusion Criteria4
- Pregnant or breastfeeding women
- Patient already treated by immunotherapy by immune checkpoint inhibitor
- Person under guardianship
- Inability to comply with medical follow-up of the trial (geographical, social or psychic reasons)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERImmuCCo Cohort
Blood sampling at initiation of immunotherapy, at the first tumor assessment, in case of severe toxicity. Urine collection at initiation of immunotherapy.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05223608
Related Trials
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
NCT0466520612 locations
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT0662577534 locations
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
NCT0655479536 locations
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
NCT0368612419 locations
COAST Therapy in Advanced Solid Tumors and Prostate Cancer
NCT050362261 location